$AVXL News Article - Anavex Life Sciences Announces ANAVEX 2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients wit https://marketwirenews.com/news-releases/anav...31497.html